Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
The DOI matches its Crossref record; 28 of the 31 references it cites were found in a registry or an index.
Abstract
Apoptosis is a genetically encoded programme of cell death that can be activated under physiological conditions and may be an important safeguard against tumour development. Regions of low oxygen (hypoxia) and necrosis are common features of solid tumours. Here we report that hypoxia induces apoptosis in oncogenically transformed cells and that further genetic alterations, such as loss of the p53 tumour-suppressor gene or overexpression of the apoptosis-inhibitor protein Bcl-2, substantially reduce hypoxia-induced cell death. Hypoxia also selects for cells with defects in apoptosis, because small numbers of transformed cells lacking p53 overtake similar cells expressing wild-type p53 when treated with hypoxia. Furthermore, highly apoptotic regions strongly correlate with hypoxic regions in transplanted tumours expressing wild-type p53, whereas little apoptosis occurs in hypoxic regions of p53-deficient tumours. We propose that hypoxia provides a physiological selective pressure in tumours for the expansion of variants that have lost their apoptotic potential, and in particular for cells acquiring p53 mutations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Giaccia and co-workers demonstrated that hypoxia can induce tumor cell apoptosis, an effect that was reduced by loss of p53 tumor suppressor function or overexpression of anti-apoptotic Bcl-2 (Graeber et al., 1996).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Graeber et al., 1996
In the citing paper
“Therefore, hypoxia can exert a selective pressure that leads to expansion of tumor cells with reduced apoptotic capacity due to, for example, TP53 mutations (Graeber et al., 1996).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Graeber et al., 1996
In the citing paper
“Hypoxia and/or HIFs can mediate chemotherapy resistance through additional mechanisms including: a) hypoxia-induced decreases in tumor cell proliferation (Tannock, 1968); b) metabolic reprogramming; c) hypoxia-driven selection of p53-mutated tumor cells with less apoptotic capacity (Graeber et al., 1996); and d) inhibition of DNA damage (Sullivan & Graham, 2009).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Graeber et al., 1996
Citations
Cites
Apoptosis in the Pathogenesis and Treatment of Disease
Thompson, C. B. (1995) · Science · doi:10.1126/science.7878464 · Cited by 6,524
Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death
Hockenbery, D., Nuñez, G., Milliman, C., Schreiber, R. D., & Korsmeyer, S. J. (1990) · Nature · doi:10.1038/348334a0 · Cited by 3,720
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. (1994) · PubMed · Cited by 3,463
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
Self-citationDranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Production of high-titer helper-free retroviruses by transient transfection.
Pear, W. S., Nolan, G. P., Scott, M. L., & Baltimore, D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.18.8392 · Cited by 2,266
The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy
Thomlinson, R. H., & Gray, L. H. (1955) · British Journal of Cancer · doi:10.1038/bjc.1955.55 · Cited by 2,219
Mice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113
The Molecular Genetics of Cancer
Bishop, J. M. (1987) · Science · doi:10.1126/science.3541204 · Cited by 1,688
Sunburn and p53 in the onset of skin cancer
Ziegler, A., Jonason, A. S., Leffellt, D. J., Simon, J. A., Sharma, H. W., Kimmelman, J., Remington, L., Jacks, T., & Brash, D. E. (1994) · Nature · doi:10.1038/372773a0 · Cited by 1,497
Self-citation
Research works printed but not linked: 9
- Vaupel, P. W. & Hockel, M. in Tumor Oxygenation (eds Vaupel, P. W., Kelleher, D. K. & Gunderoth, M.) 219–232 (Gustav Fischer, Stuttgart, 1995).
- Lord, E. M., Harwell, L. & Koch, C. J. Cancer Res. 53, 5721–5726 (1993).
- Bardeesy, N., Beckwith, J. B. & Pelletier, J. Cancer Res. 55, 215–219 (1995).
- Baker, S. J. et al. Cancer Res. 50, 7717–7722 (1990).
- Sinicrope, F. A. et al. Cancer Res. 55, 237–241 (1995).
- Bedi, A. et al. Cancer Res. 55, 1811–1816 (1995).
- Lotem, J. & Sachs, L. Cell Growth. Differ. 4, 41–47 (1993).
- Lowe, S. W. Curr. Opin. Oncol. (in the press).
- Greenblatt, M. S., Bennett, W. P., Hollstein, M. & Harris, C. C. Cancer Res. 54, 4855–4878 (1994).
Cited by
Items 101–200 of 1,006
Regulation of the p53 Tumor Suppressor Protein
Oren, M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.51.36031 · Cited by 564
Nonlinear modelling of cancer: bridging the gap between cells and tumours
Lowengrub, J. S., Frieboes, H. B., Jin, F., Chuang, Y.-L., Li, X., Macklin, P., Wise, S. M., & Cristini, V (2010) · Nonlinearity · doi:10.1088/0951-7715/23/1/r01 · Cited by 553
“hypoxia) and impaired cell genetic mechanisms can lead to multiple cell genotypes and phenotypes that select for cell survival under abnormal conditions [246], with profound consequences on the overall tumour growth, invasion and response to treatment.”
MRI of the tumor microenvironment
Gillies, R. J., Raghunand, N., Karczmar, G. S., & Bhujwalla, Z. M. (2002) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.10181 · Cited by 550
“Hence, prolonged exposure to hypoxia (either intermittent or chronic) selects for a therapy-resistant phenotype (22).”
BackgroundTumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies
Shannon, A. M., Bouchier-Hayes, D. J., Condron, C. M., & Toomey, D. (2003) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(03)00003-3 · Cited by 559
Evans, A. R., Limp-Foster, M., & Kelley, M. R. (2000) · Mutation Research/DNA Repair · doi:10.1016/s0921-8777(00)00046-x · Cited by 532
Hypoxia and Radiation Therapy: Past History, Ongoing Research, and Future Promise
Rockwell, S., Dobrucki, I., Kim, E., Marrison, S., & Vu, V. (2009) · Current Molecular Medicine · doi:10.2174/156652409788167087 · Cited by 511
Mechanisms of Glioma-Associated Neovascularization
Hardee, M. E., & Zagzag, D. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.06.030 · Cited by 475
“It has been suggested that antiangiogenic therapy leads to tissue hypoxia(95) and may select for hypoxia resistance in cancer cells.(96) In fact, one of the initial responses to antiangiogenic therapies is an increase in intratumoral hypoxia.”
BackgroundMechanism, origin, and evolution of anoxia tolerance in animals☆
Hochachka, P. W., & Lutz, P. L. (2001) · Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology · doi:10.1016/s1096-4959(01)00408-0 · Cited by 500
Tumor hypoxia and malignant progression
Vaupel, P., Mayer, A., & Höckel, M. (2004) · Methods in Enzymology · doi:10.1016/s0076-6879(04)81023-1 · Cited by 496
Role of hypoxia in the hallmarks of human cancer
Ruan, K., Song, G., & Ouyang, G. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22214 · Cited by 489
“In addition, hypoxia acts as a selective pressure during tumor growth, eliminating cells with wild-type p53 and selectively and clonally expanding cells with mutant or otherwise inactive p53; these results indicate that hypoxia-mediated selection for p53 mutant cells with diminished apoptotic potential in solid tumors…”
BackgroundApoptosis and APC in colorectal tumorigenesis.
Morin, P. J., Vogelstein, B., & Kinzler, K. W. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7950 · Cited by 489
Three-dimensional multispecies nonlinear tumor growth—I
Wise, S. M., Lowengrub, J. S., Frieboes, H. B., & Cristini, V. (2008) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2008.03.027 · Cited by 484
“Describing the dynamics of multiple cell species is crucial since the tumor microenvironment (e.g., hypoxia) and impaired cell genetic mechanisms may select for cells that survive under abnormal conditions (Graeber et al., 1996).”
BackgroundVermeulen, P. B., Gasparini, G., Fox, S. B., Colpaert, C., Marson, L. P., Gion, M., Beliën, J. A. M., de Waal, R. M. W., Van Marck, E., Magnani, E., et al. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00094-1 · Cited by 488
“Hypoxia is indeed a strong angiogenic drive and a selection pressure resulting, for instance, in the survival of TP53-mutant tumour cells with a deficient apoptotic pathway prone to other oncogenic mutations [39].”
BackgroundIdentification of redox/repair protein Ref-1 as a potent activator of p53.
Jayaraman, L., Murthy, K. G., Zhu, C., Curran, T., Xanthoudakis, S., & Prives, C. (1997) · Genes & Development · doi:10.1101/gad.11.5.558 · Cited by 481
The Hypoxic Response: Huffing and HIFing
Guillemin, K., & Krasnow, M. A. (1997) · Cell · doi:10.1016/s0092-8674(00)80176-2 · Cited by 478
Hypoxic gene expression and metastasis
Le, Q.-T., Denko, N. C., & Giaccia, A. J. (2004) · Cancer and Metastasis Reviews · doi:10.1023/b:canc.0000031768.89246.d7 · Cited by 468
Self-citationLu, C., Altieri, D. C., & Tanigawa, N. (1998) · PubMed · Cited by 501
Strategies for Targeting Protein–Protein Interactions With Synthetic Agents
Yin, H., & Hamilton, A. D. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200461786 · Cited by 453
Activating Transcription Factor 4 Is Translationally Regulated by Hypoxic Stress
Blais, J. D., Filipenko, V., Bi, M., Harding, H. P., Ron, D., Koumenis, C., Wouters, B. G., & Bell, J. C. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.17.7469-7482.2004 · Cited by 446
“The presence of hypoxic cells in solid tumors is well documented, and both clinical and experimental evidence suggests that the hypoxic microenvironment of a tumor helps to produce a more aggressive phenotype (62) by functioning as a selective pressure for the clonal expansion of apoptotically insensitive cells (16).”
BackgroundBruick, R. K. (2003) · Genes & Development · doi:10.1101/gad.1145503 · Cited by 440
“This HIF-dependent hypoxic response may provide a strong selective pressure for the accumulation of secondary mutations in tumor suppressor genes (Graeber et al. 1996).”
BackgroundRepression of c- myc Transcription by Blimp-1, an Inducer of Terminal B Cell Differentiation
Lin, Y., Wong, K.-K., & Calame, K. (1997) · Science · doi:10.1126/science.276.5312.596 · Cited by 429
MicroRNA regulation of DNA repair gene expression in hypoxic stress
Crosby, M. E., Kulshreshtha, R., Ivan, M., & Glazer, P. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2516 · Cited by 437
“Hypoxia leads to increased angiogenesis, upregulates glycolytic enzymes, and provides selective pressure for cells that are capable of evading apoptosis (5, 6).”
BackgroundBachelder, R. E., Crago, A. M., Chung, J., Wendt, M. A., Shaw, L. M., Robinson, G. S., & Mercurio, A. M. (2001) · PubMed · Cited by 487
Mechanisms of apoptosis by c-Myc
Prendergast, G. C. (1999) · Oncogene · doi:10.1038/sj.onc.1202727 · Cited by 430
“…DNA damage, and cancer chemotherapeutics (Evan et al., 1992; Harrington et al., 1994a; Wagner et al., 1994; Yao et al., 1995; Alarcon et al., 1996; Graeber et al., 1996; Jiang et al., 1996; Kang et al., 1996; Li et al., 1996; Dong et al., 1997; Koumenis and Giaccia, 1997; Zhan et al., 1997;…”
BackgroundWalsh, J. C., Lebedev, A., Aten, E., Madsen, K., Marciano, L., & Kolb, H. C. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5378 · Cited by 420
“The up-regulation of these proteins directly influences the malignancy of hypoxic tumors (102, 275, 276), including a propensity for the development of metastatic disease (23, 255, 297) by propagating cells that have lost their apoptotic potential through decreased p53 expression, increased mutant p53 or bcl-2 protein…”
23 Genetic instability induced by the tumor microenvironment
Glazer, P. M., Reynolds, T. Y., & Rockwell, S. (1997) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(97)80581-0 · Cited by 427
Effect of p53 Status on Tumor Response to Antiangiogenic Therapy
Yu, J. L., Rak, J. W., Coomber, B. L., Hicklin, D. J., & Kerbel, R. S. (2002) · Science · doi:10.1126/science.1068327 · Cited by 426
The transcriptional targets of p53 in apoptosis control
Yu, J., & Zhang, L. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.189 · Cited by 420
Tsai, M. C., Chakravarty, S., Zhu, G., Xu, J., Tanaka, K., Koch, C., Tufariello, J., Flynn, J., & Chan, J. (2006) · Cellular Microbiology · doi:10.1111/j.1462-5822.2005.00612.x · Cited by 414
“In vivo assessment of tissue hypoxia was carried out as previously described (Graeber et al., 1996; Bialik et al., 1997).”
MethodSelf-citationDrosophila p53 Is a Structural and Functional Homolog of the Tumor Suppressor p53
Ollmann, M., Young, L. M., Di Como, C. J., Karim, F., Belvin, M., Robertson, S., Whittaker, K., Demsky, M., Fisher, W. W., Buchman, A., et al. (2000) · Cell · doi:10.1016/s0092-8674(00)80626-1 · Cited by 412
“…of tive advantage to tumor cells through accrued mutations Dmp53 induces apoptosis, and inhibition of Dmp53 leading to deregulated cell proliferation and resistance function renders cells resistant to X ray–induced apoptoto cell death (Graeber et al., 1996; Kinzler and Vogelstein, sis.”
Tie receptors: new modulators of angiogenic and lymphangiogenic responses
Jones, N., Iljin, K., Dumont, D. J., & Alitalo, K. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35067005 · Cited by 418
Magnesium silicide nanoparticles as a deoxygenation agent for cancer starvation therapy
Zhang, C., Ni, D., Liu, Y., Yao, H., Bu, W., & Shi, J. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2016.280 · Cited by 413
Guillaumond, F., Leca, J., Olivares, O., Lavaut, M.-N., Vidal, N., Berthezène, P., Dusetti, N. J., Loncle, C., Calvo, E., Turrini, O., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219555110 · Cited by 413
“Moreover, combined with hypoxia, the subsequent nutrient-devoid environment provides physiological selective pressure promoting expansion of the most aggressive malignant cells, particularly those acquiring mutations in genes encoding tumor suppressor protein p53 (TP53) and v-Ki-ras2 Kirsten rat sarcoma viral oncogene…”
BackgroundInfluentialMacrophage Responses to Hypoxia
Lewis, C., & Murdoch, C. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62038-x · Cited by 413
Erler, J. T., Cawthorne, C. J., Williams, K. J., Koritzinsky, M., Wouters, B. G., Wilson, C., Miller, C., Demonacos, C., Stratford, I. J., & Dive, C. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.7.2875-2889.2004 · Cited by 400
“In addition, there is direct evidence that hypoxia in tumors selects for cells with decreased potential for apoptosis through the loss of p53 or overexpression of Bcl-2 (15).”
BackgroundDAP kinase links the control of apoptosis to metastasis
Inbal, B., Cohen, O., Polak-Charcon, S., Kopolovic, J., Vadai, E., Eisenbach, L., & Kimchi, A. (1997) · Nature · doi:10.1038/36599 · Cited by 395
Regulation of autophagy by ATF4 in response to severe hypoxia
Rzymski, T., Milani, M., Pike, L., Buffa, F., Mellor, H. R., Winchester, L., Pires, I., Hammond, E., Ragoussis, I., & Harris, A. L. (2010) · Oncogene · doi:10.1038/onc.2010.191 · Cited by 384
“Tumour hypoxia drives malignant progression, confers chemoresistance and radioresistance and is associated with a poor prognosis (Graeber et al., 1996).”
BackgroundTumor Hypoxia Has Independent Predictor Impact Only in Patients With Node-Negative Cervix Cancer
Fyles, A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.3.680 · Cited by 397
PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family
Attardi, L. D., Reczek, E. E., Cosmas, C., Demicco, E. G., McCurrach, M. E., Lowe, S. W., & Jacks, T. (2000) · Genes & Development · doi:10.1101/gad.14.6.704 · Cited by 397
“The cell death activated by p53 in response to hyperproliferation is greatly stimulated by cellular stresses such as DNA damage and hypoxia (Lowe et al. 1993; Graeber et al. 1996).”
BackgroundSelf-citationATR/CHK1 inhibitors and cancer therapy
Qiu, Z., Oleinick, N. L., & Zhang, J. (2018) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2017.09.043 · Cited by 370
Hypoxia Inhibits G1/S Transition through Regulation of p27 Expression
Gardner, L. B., Li, Q., Park, M. S., Flanagan, W. M., Semenza, G. L., & Dang, C. V. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010189200 · Cited by 390
Glucose Catabolism in Cancer Cells
Mathupala, S. P., Rempel, A., & Pedersen, P. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m108181200 · Cited by 373
Targeting glioma stem cells through combined BMI1 and EZH2 inhibition
Jin, X., Kim, L. J. Y., Wu, Q., Wallace, L. C., Prager, B. C., Sanvoranart, T., Gimple, R. C., Wang, X., Mack, S. C., Miller, T. E., et al. (2017) · Nature Medicine · doi:10.1038/nm.4415 · Cited by 383
“4b), supporting microvascular and hypoxic microenvironments as major predictors of unfavorable glioblastoma patient survival 24,25 .”
(2002) · PubMed · Cited by 385
Macrophage responses to hypoxia: relevance to disease mechanisms
Lewis, J. S., Lee, J. A., Underwood, J. C. E., Harris, A. L., & Lewis, C. E. (1999) · Journal of Leukocyte Biology · doi:10.1002/jlb.66.6.889 · Cited by 386
“In tumor cells this is mediated, in part, by absence of the wild-type form of the tumor suppressor gene, p53 [35], but the mechanisms operating in macrophages have yet to be determined.”
BackgroundBiological consequences of tumor hypoxia
HOCKEL, M. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90211-8 · Cited by 382
Impact of Tumor Hypoxia and Anemia on Radiation Therapy Outcomes
Harrison, L. B., Chadha, M., Hill, R. J., Hu, K., & Shasha, D. (2002) · The Oncologist · doi:10.1634/theoncologist.7-6-492 · Cited by 376
Cairns, R., Papandreou, I., & Denko, N. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0002 · Cited by 370
“Finally, hypoxia has also been shown to select for apoptosis-resistant cells in model tumors (42).”
BackgroundTumor Hypoxia in Cancer Therapy
Brown, J. M. (2007) · Methods in Enzymology · doi:10.1016/s0076-6879(07)35015-5 · Cited by 359
Bialik, S., Geenen, D. L., Sasson, I. E., Cheng, R., Horner, J. W., Evans, S. M., Lord, E. M., Koch, C. J., & Kitsis, R. N. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119656 · Cited by 373
Self-citationKoritzinsky, M., Magagnin, M. G., van den Beucken, T., Seigneuric, R., Savelkouls, K., Dostie, J., Pyronnet, S., Kaufman, R. J., Weppler, S. A., Voncken, J. W., et al. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7600998 · Cited by 363
“The clinical importance of tumor hypoxia results from its ability to protect cells against both radiation and chemotherapy and from the fact that it can provide a selection pressure for apoptotically resistant cells (Graeber et al, 1996).”
BackgroundIdentification of a novel stress-responsive gene Hi95 involved in regulation of cell viability
Budanov, A. V., Shoshani, T., Faerman, A., Zelin, E., Kamer, I., Kalinski, H., Gorodin, S., Fishman, A., Chajut, A., Einat, P., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205877 · Cited by 362
“Among genes involved in hypoxia-mediated apoptosis are HIF-1 independent p53 (An et al., 1998; Graeber et al., 1994, 1996) and Gadd153 (Price and Calderwood, 1992; McCullough et al., 2001) as well as HIF-1dependent genes Nip3 (Bruick, 2000; Vande Velde et al., 2000; Sowter et al., 2001) and a…”
BackgroundPedersen, P. L., Mathupala, S., Rempel, A., Geschwind, J. F., & Ko, Y. H. (2002) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/s0005-2728(02)00248-7 · Cited by 356
The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy
Albadari, N., Deng, S., & Li, W. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1613370 · Cited by 351
“For instance, hypoxia is able to select for cells expressing mutations in both p53, a tumor suppressor gene, and Bcl-2, an apoptosis-inhibiting protein, in oncogenically transformed cells [7].”
BackgroundHypoxia and Anemia: Factors in Decreased Sensitivity to Radiation Therapy and Chemotherapy?
Harrison, L., & Blackwell, K. (2004) · The Oncologist · doi:10.1634/theoncologist.9-90005-31 · Cited by 349
“This allows for the emergence of a dominant resistant cell population with mutant p53, since such cells would be resistant to apoptosis [2, 19-22 ].”
BackgroundExpansion of human SCID-repopulating cells under hypoxic conditions
Danet, G. H., Pan, Y., Luongo, J. L., Bonnet, D. A., & Simon, M. C. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17669 · Cited by 345
“It has been shown that hypoxia can induce G1 arrest in tumor (49, 50) and endothelial cells (51).”
Kimura, H., Braun, R. D., Ong, E. T., Hsu, R., Secomb, T. W., Papahadjopoulos, D., Hong, K., & Dewhirst, M. W. (1996) · PubMed · Cited by 364
Tumor hypoxia: A target for selective cancer therapy
Kizaka‐Kondoh, S., Inoue, M., Harada, H., & Hiraoka, M. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01395.x · Cited by 352
Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies
Brown, J. M. (2000) · Molecular Medicine Today · doi:10.1016/s1357-4310(00)01677-4 · Cited by 350
Koumenis, C., Alarcon, R., Hammond, E., Sutphin, P., Hoffman, W., Murphy, M., Derr, J., Taya, Y., Lowe, S. W., Kastan, M., et al. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.4.1297-1310.2001 · Cited by 346
“In contrast to DNA damage, hypoxia is a physiological inducer of the p53 tumor suppressor gene product (15) and can act as a selective pressure during tumor growth for the elimination of cells with wild-type (wt) p53 and the clonal expansion of cells with mutant or otherwise inactive p53 protein (16).”
BackgroundSelf-citationHIF-1α Induces Genetic Instability by Transcriptionally Downregulating MutSα Expression
Koshiji, M., To, K. K.-W., Hammer, S., Kumamoto, K., Harris, A. L., Modrich, P., & Huang, L. E. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.02.015 · Cited by 346
Varia, M. A., Calkins-Adams, D. P., Rinker, L. H., Kennedy, A. S., Novotny, D. B., Fowler, W. C., & Raleigh, J. A. (1998) · Gynecologic Oncology · doi:10.1006/gyno.1998.5163 · Cited by 342
Parahydrogen‐Based Hyperpolarization for Biomedicine
Hövener, J., Pravdivtsev, A. N., Kidd, B., Bowers, C. R., Glöggler, S., Kovtunov, K. V., Plaumann, M., Katz‐Brull, R., Buckenmaier, K., Jerschow, A., et al. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201711842 · Cited by 346
p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis.
Tashiro, H., Isacson, C., Levine, R. L., Kurman, R. J., Cho, K. R., & Hedrick, L. (1997) · Europe PMC (PubMed Central) · Cited by 345
Developing new metal-based therapeutics: challenges and opportunities
Hambley, T. W. (2007) · Dalton Transactions · doi:10.1039/b706075k · Cited by 337
Willis, A., Jung, E. J., Wakefield, T., & Chen, X. (2004) · Oncogene · doi:10.1038/sj.onc.1207396 · Cited by 330
“Wild-type p53 is activated in response to cellular stresses, such as oncogene activation (Lowe and Ruley, 1993), DNA damage (Nelson and Kastan, 1994), and hypoxia (Graeber et al., 1996).”
BackgroundMorry, J., Ngamcherdtrakul, W., & Yantasee, W. (2017) · Redox Biology · doi:10.1016/j.redox.2016.12.011 · Cited by 333
“In order to support tumor growth and proliferation in these hypoxic microenvironments, cancer cells undergo several changes to adapt to this oxygen- and nutrient-deprived state, including genotype selections favouring survival (such as TP53 mutation [55]) and activation of hypoxia inducible factor-1 (HIF-1) transcript…”
Protein Glycosylation and Tumor Microenvironment Alterations Driving Cancer Hallmarks
Peixoto, A., Relvas-Santos, M., Azevedo, R., Santos, L. L., & Ferreira, J. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00380 · Cited by 334
“Moreover, tumor hypoxia selects clones expressing mutant p53, facilitating the clonal expansion of cells that have a dominant-negative effect on the wild-type cells, thus evading growth suppression (148).”
BackgroundMicroenvironment-induced cancer metastasis
Rofstad, E. K. (2000) · International Journal of Radiation Biology · doi:10.1080/095530000138259 · Cited by 329
“…of system (Guillemin and Krasnow 1997, Semenza 1999).cell variants that have lost their apoptotic potential, and in particular cell variants that have acquired Malignant cells show increased expression of a large number of genes during exposure to hypoxiaTP53 mutations (Graeber et al. 1996) .”
BackgroundInfluentialThe hypoxia-inducible factor-1α is a negative factor for tumor therapy
Unruh, A., Ressel, A., Mohamed, H. G., Johnson, R. S., Nadrowitz, R., Richter, E., Katschinski, D. M., & Wenger, R. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206385 · Cited by 334
“The tumor suppressor protein p53 has been suggested to be induced by severe hypoxia (0.02% O2) and to cause apoptosis, resulting in a selective pressure against cells expressing wild-type p53 (Graeber et al., 1996).”
BackgroundInfluentialThe p53 Tumor Suppressor Gene: From Molecular Biology to Clinical Investigation
SOUSSI, T. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06705.x · Cited by 332
p53, cancer and the immune response
Blagih, J., Buck, M. D., & Vousden, K. H. (2020) · Journal of Cell Science · doi:10.1242/jcs.237453 · Cited by 333
Hypoxia Links ATR and p53 through Replication Arrest
Hammond, E. M., Denko, N. C., Dorie, M. J., Abraham, R. T., & Giaccia, A. J. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.6.1834-1843.2002 · Cited by 324
“During tumor growth, hypoxia can act as a selective pressure for the elimination of cells with wild-type p53 and the clonal expansion of cells with mutant or otherwise inactive p53 protein (21).”
BackgroundSelf-citationCoccolini, F. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i41.6979 · Cited by 325
Metastasis: cancer cell’s escape from oxidative stress
Pani, G., Galeotti, T., & Chiarugi, P. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9225-4 · Cited by 313
Dehdashti, F., Grigsby, P. W., Mintun, M. A., Lewis, J. S., Siegel, B. A., & Welch, M. J. (2003) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(02)04477-2 · Cited by 326
The hypoxic tumour microenvironment and metastatic progression
Subarsky, P., & Hill, R. P. (2003) · Clinical & Experimental Metastasis · doi:10.1023/a:1022939318102 · Cited by 327
“We have focused here on the role of hypoxia in alteration of the expression of genes that may be involved in the metastatic process but there is also evidence that the microenvironmental conditions in tumours can cause gene mutations [40, 132] and select for resistance to apoptosis [24].”
BackgroundHypoxic cervical cancers with low apoptotic index are highly aggressive.
Höckel, M., Schlenger, K., Höckel, S., & Vaupel, P. W. (1999) · PubMed · Cited by 387
Three-dimensional context regulation of metastasis
Erler, J. T., & Weaver, V. M. (2009) · Clinical & Experimental Metastasis · doi:10.1007/s10585-008-9209-8 · Cited by 313
“Transformation of cells may also be driven by hypoxia, which induces oncogene expression, enhances DNA mutation rate, and selects for cells with increased apoptotic thresholds [54,97–99].”
BackgroundAbrogation of p53-Induced Apoptosis by the Hepatitis B Virus X Gene
Wang, X. W. (2003) · Hepatocellular Carcinoma · doi:10.1385/1-59259-079-9:57 · Cited by 321
Redox mechanisms switch on hypoxia-dependent epithelial–mesenchymal transition in cancer cells
Cannito, S., Novo, E., Compagnone, A., Valfrè di Bonzo, L., Busletta, C., Zamara, E., Paternostro, C., Povero, D., Bandino, A., Bozzo, F., et al. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn216 · Cited by 309
Hypoxia-inducible Factor and Its Biomedical Relevance
Huang, L. E., & Bunn, H. F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.r200030200 · Cited by 315
The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway.
Wang, X. W., Vermeulen, W., Coursen, J. D., Gibson, M., Lupold, S. E., Forrester, K., Xu, G., Elmore, L., Yeh, H., Hoeijmakers, J. H., et al. (1996) · Genes & Development · doi:10.1101/gad.10.10.1219 · Cited by 313
Investigating hypoxic tumor physiology through gene expression patterns
Denko, N. C., Fontana, L. A., Hudson, K. M., Sutphin, P. D., Raychaudhuri, S., Altman, R., & Giaccia, A. J. (2003) · Oncogene · doi:10.1038/sj.onc.1206703 · Cited by 305
“Normoxic expression of BNIP3/ BNIP3L in the VHL-negative tumor cells could lead to the selection of cells with a second site mutation somewhere downstream in the apoptotic signaling pathway (Graeber et al., 1996).”
BackgroundSelf-citationAdvances in Radiotherapy and Implications for the Next Century: A Historical Perspective
Connell, P. P., & Hellman, S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-07-6871 · Cited by 283
“More recent studies have shown that tumor hypoxia can also select for more aggressive tumor cells, including those with p53 mutations (53).”
BackgroundBlais, J. D., Addison, C. L., Edge, R., Falls, T., Zhao, H., Wary, K., Koumenis, C., Harding, H. P., Ron, D., Holcik, M., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.01145-06 · Cited by 297
“The ability of tumor cells to survive and adapt to hypoxic microenvionments can be attributed to the regulation of several key mechanisms, including the loss of pathways that can induce cell death (28), the stimulation of angiogenesis to increase tumor oxygenation (87), and the capability to strictly regulate energy h…”
BackgroundRole of the Crosstalk between Autophagy and Apoptosis in Cancer
Su, M., Mei, Y., & Sinha, S. (2013) · Journal of Oncology · doi:10.1155/2013/102735 · Cited by 306
“Hypoxia has previously been reported to select cells with defective apoptosis in solid tumors [40].”
Birner, P., Schindl, M., Obermair, A., Breitenecker, G., & Oberhuber, G. (2001) · PubMed · Cited by 362
The Role of Apoptosis in the Regulation of Trophoblast Survival and Differentiation during Pregnancy
Straszewski-Chavez, S. L., Abrahams, V. M., & Mor, G. (2005) · Endocrine Reviews · doi:10.1210/er.2005-0003 · Cited by 307
Dhandapani, K. M., Mahesh, V. B., & Brann, D. W. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04633.x · Cited by 298
Repression of the miR‐17‐92 cluster by p53 has an important function in hypoxia‐induced apoptosis
Yan, H., Xue, G., Mei, Q., Wang, Y., Ding, F., Liu, M., Lu, M., Tang, Y., Yu, H., & Sun, S. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.214 · Cited by 300
“Graeber et al (1996) showed that p53 positive tumours underwent significant hypoxia-induced apoptosis, whereas match p53-null tumours did not.”
BackgroundThe tumor microenvironment and metastatic disease
Lunt, S. J., Chaudary, N., & Hill, R. P. (2009) · Clinical & Experimental Metastasis · doi:10.1007/s10585-008-9182-2 · Cited by 298
Raleigh, J. A., Chou, S.-C., Arteel, G. E., & Horsman, M. R. (1999) · Radiation Research · doi:10.2307/3580034 · Cited by 304
The Unfolded Protein Response: A Novel Component of the Hypoxic Stress Response in Tumors
Feldman, D. E., Chauhan, V., & Koong, A. C. (2005) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-05-0221 · Cited by 295
“The demonstration of hypoxia-mediated clonal expansion of cells with diminished apoptotic potential supports this concept (3).”
Foundations in Cancer Research p53 and ATM: Cell Cycle, Cell Death, and Cancer
(1997) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60095-0 · Cited by 300
Kaidi, A., Qualtrough, D., Williams, A. C., & Paraskeva, C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0425 · Cited by 300
“pressure that drives clonal progression of tumors (20).”
Gene Expression Induced by Cerebral Ischemia: An Apoptotic Perspective
MacManus, J. P., & Linnik, M. D. (1997) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/aj.jcbfm.9590266 · Cited by 300
Paterson, B. M., & Donnelly, P. S. (2011) · Chemical Society Reviews · doi:10.1039/c0cs00215a · Cited by 299
Decaudin, D., Geley, S., Hirsch, T., Castedo, M., Marchetti, P., Macho, A., Kofler, R., & Kroemer, G. (1997) · PubMed · Cited by 333
Jensen, R. L. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9827-2 · Cited by 287
Metadata
- Authors
- Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., & Giaccia, A. J.
- Affiliations
- Stanford Medicine (US)
- Howard Hughes Medical Institute (US)
- Massachusetts Institute of Technology (US)
- University of Pennsylvania (US)
- Cold Spring Harbor Laboratory (US)
- Venue
- Nature
- Published
- 1996-01
- Volume
- 379
- Issue
- 6560
- Pages
- 88-91
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2028999918
- Cited by
- 2,300
- References
- 31
- Citations by year
- 2026: 7 · 2025: 13 · 2024: 16 · 2023: 30 · 2022: 27 · 2021: 55 · 2020: 39 · 2019: 37 · 2018: 37 · 2017: 51 · 2016: 56 · 2015: 56 · 2014: 41 · 2013: 70 · 2012: 78
- FWCI
- 52.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- tumor hypoxia, apoptosis, solid tumors, p53, Bcl-2, p53 deficiency, tumor necrosis, tumor heterogeneity, tumor suppressor
- MeSH terms
- Animals, Cell Line, Transformed, Cell Transformation, Neoplastic, Neoplasm Transplantation, Neoplasms, Oxygen, Proto-Oncogene Proteins, Receptors, Estrogen, Tamoxifen, Cell Hypoxia, Genes, p53, Proto-Oncogene Proteins c-myc, Apoptosis, Proto-Oncogene Proteins c-bcl-2, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.